Inhaled antibiotics in cystic fibrosis: a review.
OBJECTIVE
To provide an overview of aerosol drug therapy, including physical considerations and aerosol drug delivery systems, and to review clinical experience with inhaled antibiotics in cystic fibrosis (CF) when used as adjunctive therapy to intravenous therapy for acute pulmonary exacerbations and chronic, suppressive therapy.


METHODS
A MEDLINE search (1966-1995) of English-language literature describing the use of inhaled antibiotics for the management of CF.


METHODS
All articles were considered for possible inclusion in the review. Pertinent information as judged by the authors was selected for discussion.


RESULTS
The use of inhaled antibiotics as adjunctive therapy to systemic therapy for acute exacerbations did not improve pulmonary function tests, increase hospital discharge rate, or permanently eradicate sputum Pseudomonas. Clinical trials of inhaled antibiotics as suppressive therapy yielded variable results. Individually, four trials documented a significant improvement in pulmonary function, three trials documented a slower decline in pulmonary function, and four trials reported a reduced frequency of hospitalizations. However, the trials were unable to collectively document a prolonged beneficial effect of inhaled antibiotics on pulmonary function, sputum bacterial density, and frequency of hospitalizations.


CONCLUSIONS
Clinical trials conducted thus far suggest no role for inhaled antibiotics in the treatment of acute pulmonary exacerbations in patients with CF. Aerosolized antibiotics used as suppressive therapy may be useful in certain patients, but their use should be limited to select patients based on individual response to therapy. Additional long-term, well-controlled trials of inhaled antibiotics as suppressive therapy are needed before routine use can be recommended.
Toso
C
C
School of Pharmacy, University of North Carolina at Chapel Hill 27599, USA.
Williams
D M
DM
Noone
P G
PG
D000280:Administration, Inhalation; D000336:Aerosols; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003550:Cystic Fibrosis / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D006760:Hospitalization; D006801:Humans; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy*
D000336:Aerosols; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents